Avirmax Inc., a leading biopharmaceutical company based in San Francisco, is set to present two groundbreaking scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore from May 7th to 11th, 2024.
The first presentation titled “Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys” will be delivered by Dr. Read You, highlighting Avirmax’s lead candidate ABI-110 for wet AMD and PCV. This presentation will showcase the significant advancements made in macular retina targeting using the proprietary novel capsid AAV2.N54 developed through capsid engineering.
The second presentation titled “Comprehensive Head-to-Head Comparisons Demonstrated Key Advantages of The Sf9 System Over HEK293 in rAAV Manufacturing” will be presented by Dr. Read You as well. This presentation will focus on the comparative analysis between AAV vectors manufactured using the traditional HEK293 plasmid transfection system and the Sf9/baculoviral infection system, showcasing the superior advantages of the Sf9 system in terms of yields, purity, and potency.
Avirmax will also have an exhibitor booth #818 at the ASGCT annual meeting, where attendees can learn more about the latest progress and data package of Avirmax’s cutting-edge technologies in gene and cell therapy for ocular diseases.
Avirmax Inc. is revolutionizing the field of gene and cell therapy with its innovative AAV engineering technologies and the Sf9-based AAV manufacturing platform. To stay updated on Avirmax’s latest developments and achievements, visit their website at avirmax.com.
For more information about Avirmax Inc. and their groundbreaking research, please refer to the following reference:
– Liu S, Li J, Peraramelli S, Luo N, Chen A, Dai M, Liu F, Yu Y, Leib RD, Li Y, Lin K, Huynh D, Li S, Ou L. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Mol Ther. 2023 Nov 20:S1525-0016(23)00623-8.
For any inquiries or to get in touch with Avirmax Inc., contact June Song, Associate Director for Operations, at +1-510-641-0201 or visit their headquarters located at 25503 Whitesell Street, Hayward, CA 94545, USA.
[Include Avirmax Logo: https://mma.prnewswire.com/media/1915870/Avirmax__Logo.jpg?p=original%5D
Source link
